Pharsight

Drug Patents Expiring in 2024

1. Abilify patents expiration

ABILIFY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(3 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(4 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(4 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(9 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(7 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(7 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(7 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

3. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(3 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

4. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
ABRAXANE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8314156

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(3 months from now)

US7923536

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(3 months from now)

US8138229

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(3 months from now)

US7820788 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

5. Acular Ls patents expiration

Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain; A method of treating ocular pain and/or enhancing ocular comfort; A met...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage

ACULAR LS family patents

Family Patents

6. Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(5 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents

7. Adasuve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(2 months from now)

US8991387 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(2 months from now)

US7458374 ALEXZA PHARMS Method and apparatus for vaporizing a compound
Aug, 2024

(5 months from now)

US7537009 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2024

(8 months from now)

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ADASUVE family patents

Family Patents

8. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987229 TEVA PHARM Process for preparing a medicament
Sep, 2024

(6 months from now)

US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

9. Aldara patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(7 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage

ALDARA family patents

Family Patents

10. Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Market Authorisation Date: 14 September, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents

11. Aloxi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(5 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage

ALOXI family patents

Family Patents

12. Alphagan P patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(4 days from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's drug patent expiration?
More Information on Dosage

ALPHAGAN P family patents

Family Patents

13. Altabax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(6 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

Family Patents

14. Amitiza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort
Sep, 2024

(6 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

15. Arikayce Kit patents expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137 INSMED INC Sustained release of antiinfectives
Apr, 2024

(a month from now)

US9827317 INSMED INC Sustained release of antiinfectives
Apr, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination anti...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

16. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

17. Auryxia patents expiration

AURYXIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(8 days ago)

US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(8 days ago)

US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(8 days ago)

US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(8 days ago)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

Family Patents

18. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920377 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(8 months from now)

US9833573 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

19. Bosulif patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE42376

(Pediatric)

PF PRISM CV Substituted 3-cyanoquinolines
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 26, 2030
New Indication (I) Sep 26, 2026
Pediatric Exclusivity (PED) Mar 26, 2027

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

20. Brilinta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) May 9, 2025
Pediatric Exclusivity (PED) Nov 9, 2025

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and ...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

21. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(7 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

22. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(7 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

23. Cabometyx patents expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

24. Children's Advil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(2 months from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL family patents

Family Patents

25. Children's Advil Allergy Sinus patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(2 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL ALLERGY SINUS family patents

Family Patents

26. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(5 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

27. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544 NALPROPION Compositions for affecting weight loss
Apr, 2024

(a month from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity
Jul, 2024

(4 months from now)

US7462626 NALPROPION Compositions for affecting weight loss
Jul, 2024

(4 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

28. Daliresp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(10 days from now)

US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(10 days from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(10 days from now)

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage

DALIRESP family patents

Family Patents

29. Defencath patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541393 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(8 months from now)

US9339036 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 15, 2028
Generating Antibiotic Incentives Now (GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 2032-11-15

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION;N/A

More Information on Dosage

DEFENCATH family patents

Family Patents

30. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

31. Dexilant Solutab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

32. Dextenza patents expiration

DEXTENZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: NA

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents

33. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Aug, 2024

(6 months from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: NA

Dosage: GEL;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

34. Diprivan patents expiration

DIPRIVAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(9 months from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

35. Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
May, 2024

(2 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

DUAVEE family patents

Family Patents

36. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

37. Dutrebis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(a month from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DUTREBIS family patents

Family Patents

38. Dymista patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(2 days from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

39. Entresto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

40. Envarsus Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US11077096 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(6 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage

ENVARSUS XR family patents

Family Patents

41. Epiduo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202 GALDERMA LABS LP Method for treatment of common acne
Sep, 2024

(6 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

42. Equetro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine
May, 2024

(2 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EQUETRO before it's drug patent expiration?
More Information on Dosage

EQUETRO family patents

Family Patents

43. Evekeo Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 ARBOR PHARMS LLC Taste-masked pharmaceutical compositions
Apr, 2024

(a month from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

EVEKEO ODT family patents

Family Patents

44. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(8 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

45. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(8 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(8 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

46. Exservan patents expiration

EXSERVAN's oppositions filed in EPO
EXSERVAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 MITSUBISHI HOLDINGS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(a month from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

EXSERVAN family patents

Family Patents

47. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
M (M) May 8, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

48. Fenoglide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173847 SALIX Tablet comprising a fibrate
Oct, 2024

(7 months from now)

US8481078 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(7 months from now)

US8124125 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(7 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate
Dec, 2024

(9 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total tri...

Dosage: TABLET;ORAL

How can I launch a generic of FENOGLIDE before it's drug patent expiration?
More Information on Dosage

FENOGLIDE family patents

Family Patents

49. Fentora patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl
Dec, 2024

(10 months from now)

US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Dec, 2024

(10 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage

FENTORA family patents

Family Patents

50. Finacea patents expiration

FINACEA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435498 LEO PHARMA AS Penetrating pharmaceutical foam
Mar, 2024

(3 days from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage

FINACEA family patents

Family Patents

51. Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device
Nov, 2024

(8 months from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

52. Fosrenol patents expiration

FOSRENOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(5 months from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(5 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: POWDER;ORAL

How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage

FOSRENOL family patents

Family Patents

53. Fotivda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2024

(a month from now)

US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

Family Patents

54. Fycompa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2024

(3 months from now)

Drugs and Companies using PERAMPANEL ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older; Treatment of partial-onset seizures with or without secondarily genera...

Dosage: SUSPENSION;ORAL

How can I launch a generic of FYCOMPA before it's drug patent expiration?
More Information on Dosage

FYCOMPA family patents

Family Patents

55. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(a month ago)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(10 days from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(10 days from now)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

56. Gralise patents expiration

GRALISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7438927 ALMATICA Methods of treatment using a gastric retained gabapentin dosage
Feb, 2024

(10 hours ago)

Drugs and Companies using GABAPENTIN ingredient

Market Authorisation Date: 28 January, 2011

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

How can I launch a generic of GRALISE before it's drug patent expiration?
More Information on Dosage

GRALISE family patents

Family Patents

57. Hycamtin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods
Dec, 2024

(9 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

HYCAMTIN family patents

Family Patents

58. Ilevro patents expiration

ILEVRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(3 months from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage

ILEVRO family patents

Family Patents

59. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

60. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

61. Ionsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902 THE MEDICINES CO Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof
Apr, 2024

(a month from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

IONSYS family patents

Family Patents

62. Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(a month from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 21 December, 2011

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

63. Ixempra Kit patents expiration

IXEMPRA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(5 months from now)

Drugs and Companies using IXABEPILONE ingredient

Market Authorisation Date: 16 October, 2007

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents

64. Kuvan patents expiration

KUVAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(8 months from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(8 months from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(8 months from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(8 months from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin
Nov, 2024

(8 months from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(8 months from now)

US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(8 months from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2007

Treatment: To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Metho...

Dosage: TABLET;ORAL

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

65. Kynmobi patents expiration

KYNMOBI's oppositions filed in EPO
KYNMOBI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: NA

Dosage: FILM;SUBLINGUAL

More Information on Dosage

KYNMOBI family patents

Family Patents

66. Latisse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(2 months from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of stimulating hair growth; Method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage

LATISSE family patents

Family Patents

67. Latuda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(5 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents

68. Lazanda patents expiration

LAZANDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216604 BTCP PHARMA Method of managing or treating pain
Oct, 2024

(7 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

LAZANDA family patents

Family Patents

69. Leqvio patents expiration

Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(a month ago)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(10 days from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(10 days from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(10 days from now)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 2025-12-22

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

70. Linzess patents expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(29 days ago)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(29 days ago)

US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(29 days ago)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(29 days ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 12, 2026

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

71. Livalo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium
Aug, 2024

(5 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent
Aug, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 16, 2022
Pediatric Exclusivity (PED) Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage

LIVALO family patents

Family Patents

72. Lonhala Magnair Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372 SUNOVION RESP Inhalation therapy device
Nov, 2024

(8 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

73. Lupkynis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

Family Patents

74. Lynparza patents expiration

LYNPARZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(7 months from now)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(14 days from now)

US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(14 days from now)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(14 days from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based ch...

Dosage: TABLET;ORAL

How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage

LYNPARZA family patents

Family Patents

75. Mavenclad patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(a month from now)

US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a s...

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage

MAVENCLAD family patents

Family Patents

76. Megace Es patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a month from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a month from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a month from now)

US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a month from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a month from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage

MEGACE ES family patents

Family Patents

77. Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2024

(15 days from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

Market Authorisation Date: 27 June, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

78. Methylin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production
Oct, 2024

(7 months from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of METHYLIN before it's drug patent expiration?
More Information on Dosage

METHYLIN family patents

Family Patents

79. Mirvaso patents expiration

MIRVASO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(2 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage

MIRVASO family patents

Family Patents

80. Movantik patents expiration

MOVANTIK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500 REDHILL Polymer conjugates of opioid antagonists
Jun, 2024

(4 months from now)

US8067431 REDHILL Chemically modified small molecules
Dec, 2024

(9 months from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage

MOVANTIK family patents

Family Patents

81. Moviprep patents expiration

MOVIPREP's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(6 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(6 months from now)

How can I launch a generic of MOVIPREP before it's drug patent expiration?
More Information on Dosage

MOVIPREP family patents

Family Patents

82. Mulpleta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: 2022-07-31

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

MULPLETA family patents

Family Patents

83. Myrbetriq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(2 months from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(2 months from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(2 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ be